- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06397443
Ready to Sail: Evaluating Sailing's Feasibility as Ergotherapy (PaS)
Pronti A Salpare: Studio di fattibilità Sull'Impatto Della Vela Come Ergoterapia in Pazienti Con Malattie Rare Scheletriche - Ready to Sail: Evaluating Sailing's Feasibility as Ergotherapy for Rare Skeletal Diseases
Background Individuals with rare skeletal disorders frequently experience psychological distress, social isolation, unmet needs, and significant challenges due to limited treatment options. Adventure Therapy, employing exposure to natural environments, has shown promise in improving self-esteem, autonomy, and social skills in chronic illness and disability populations. This pilot study explores the feasibility and preliminary efficacy of a sailing-based intervention for enhancing physical, social, and psychological well-being in this specific population.
Outcome Measures The primary outcome is to investigates the feasibility of sailing to improve well-being and quality of life in patients living with rare skeletal disorders.
Furthermore, the investigators hypothesize that participation in a sailing program led by occupational therapists will lead to improvements in:
- Movement confidence: assessing whether sailing enhances participants' ability to move and perform daily activities.
- Mental health: evaluating if sailing reduces anxiety and fear and promotes self-esteem.
- Social interaction: exploring if sailing fosters social connection and reduces feelings of isolation.
Methods The study will use a prospective, single-arm, longitudinal design. Eight participants with rare skeletal disorders will be enrolled in a 5-day sailing-based occupational therapy intervention. Comprehensive pre- and post-intervention assessments will measure psychosocial factors, quality of life, functional mobility, kinesiophobia, and body segment movement using questionnaires and functional scales.
Study Overview
Status
Intervention / Treatment
Detailed Description
Rare skeletal diseases represent a significant global health burden, affecting millions of people worldwide. These chronic, debilitating conditions necessitate the development of optimized clinical pathways and comprehensive support systems.
Adventure therapy (AT) has emerged as a promising intervention for individuals with chronic conditions, demonstrating improvements in self-esteem, autonomy, and social skills. Sailing, a form of AT, offers opportunities for physical activity, social inclusion, and emotional well-being in individuals with disabilities.
This study aims to assess the feasibility of using sailing as an occupational therapy intervention for patients with rare skeletal diseases. We hypothesize that sailing can enhance physical, cognitive, and social functioning in this patient population.
A pilot program of sailing lessons for patients with rare skeletal diseases will be conducted. Participants will undergo assessments of physical, cognitive, and social skills before and after the intervention.
This study will be the first to explore the use of sailing-based AT for this patient population. The findings will inform the development of larger-scale studies and contribute to the optimization of rehabilitation programs for this patient population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bologna, Italy, 40136
- IRCCS Istituto Ortopedico Rizzoli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals of any gender
- Diagnosis of a rare skeletal disease, confirmed clinically and/or molecularly
- Age 12 years or older
- No history of surgery within six months prior to study enrollment.
Exclusion Criteria:
- Individuals undergoing diagnostic evaluation for a rare skeletal disease
- Participants younger than 12 years of age.
- Individuals who underwent surgery within the preceding 6 months.
- Participants with fractures or musculoskeletal injuries sustained within the past year.
- Individuals who were unable to provide written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients with rare skeletal disorders
5-day sailing activity
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health-related Quality of Life
Time Frame: T0: Baseline
|
EuroQol 5-Dimension (EQ-5D) instrument offers valuable information about patient-reported health status. The questionnaire consists of two sections-descriptive system and visual analog scale (VAS)-and yields two scores: Index Value (IV), and overall health status (VAS). In the descriptive system section, patients report their level of problems in five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-and rate their health on a 5-level options for adults, and 3-level for adolescents and children. Based on the pattern of their responses, patients generate a health profile ranging from best health (11111 = highest level) to worst health (55555 = lowest level). Each health profile is transformed into an IV, that varies from 0 (absence of life/death) to 1 (perfect health). The VAS measures the patients' overall health status, with a score ranging from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). |
T0: Baseline
|
|
Health-related Quality of Life
Time Frame: T1: up to 2 weeks
|
EuroQol 5-Dimension (EQ-5D) instrument offers valuable information about patient-reported health status. The questionnaire consists of two sections-descriptive system and visual analog scale (VAS)-and yields two scores: Index Value (IV), and overall health status (VAS). In the descriptive system section, patients report their level of problems in five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-and rate their health on a 5-level options for adults, and 3-level for adolescents and children. Based on the pattern of their responses, patients generate a health profile ranging from best health (11111 = highest level) to worst health (55555 = lowest level). Each health profile is transformed into an IV, that varies from 0 (absence of life/death) to 1 (perfect health). The VAS measures the patients' overall health status, with a score ranging from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). |
T1: up to 2 weeks
|
|
Health-related Quality of Life
Time Frame: T2: up to 3 weeks
|
EuroQol 5-Dimension (EQ-5D) instrument offers valuable information about patient-reported health status. The questionnaire consists of two sections-descriptive system and visual analog scale (VAS)-and yields two scores: Index Value (IV), and overall health status (VAS). In the descriptive system section, patients report their level of problems in five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-and rate their health on a 5-level options for adults, and 3-level for adolescents and children. Based on the pattern of their responses, patients generate a health profile ranging from best health (11111 = highest level) to worst health (55555 = lowest level). Each health profile is transformed into an IV, that varies from 0 (absence of life/death) to 1 (perfect health). The VAS measures the patients' overall health status, with a score ranging from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). |
T2: up to 3 weeks
|
|
Health-related Quality of Life
Time Frame: T3: up to 3 months
|
EuroQol 5-Dimension (EQ-5D) instrument offers valuable information about patient-reported health status. The questionnaire consists of two sections-descriptive system and visual analog scale (VAS)-and yields two scores: Index Value (IV), and overall health status (VAS). In the descriptive system section, patients report their level of problems in five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-and rate their health on a 5-level options for adults, and 3-level for adolescents and children. Based on the pattern of their responses, patients generate a health profile ranging from best health (11111 = highest level) to worst health (55555 = lowest level). Each health profile is transformed into an IV, that varies from 0 (absence of life/death) to 1 (perfect health). The VAS measures the patients' overall health status, with a score ranging from 0 ("The worst health you can imagine") to 100 ("The best health you can imagine"). |
T3: up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-esteem
Time Frame: T0: Baseline
|
Rosenberg Self-Esteem Scale: 10-item scales, ranging from 0-30.
Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
|
T0: Baseline
|
|
Self-esteem
Time Frame: T1: up to 2 weeks
|
Rosenberg Self-Esteem Scale: 10-item scales, ranging from 0-30.
Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
|
T1: up to 2 weeks
|
|
Self-esteem
Time Frame: T2: up to 3 weeks
|
Rosenberg Self-Esteem Scale: 10-item scales, ranging from 0-30.
Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
|
T2: up to 3 weeks
|
|
Self-esteem
Time Frame: T3: up to 3 months
|
Rosenberg Self-Esteem Scale is a 10-item scale that assesses the self-esteem, ranging from 0-30.
Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.
|
T3: up to 3 months
|
|
Motor Coordination
Time Frame: T0: Baseline
|
Performance Oriented Mobility Assesment (Tinetti Balance Scale) is an administered 16-item task-oriented test that measures gait and balance abilities, primarily to assess fall risk.
It uses a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16.
The total score (Fall Risk) ranges from 0 to 28, with higher scores indicating better balance and gait performance (19 or below=High risk of falls; 20-23=Moderate risk of falls; 24-28=Low risk of falls).
|
T0: Baseline
|
|
Motor Coordination
Time Frame: T1: up to 2 weeks
|
Performance Oriented Mobility Assesment (Tinetti Balance Scale) is an administered 16-item task-oriented test that measures gait and balance abilities, primarily to assess fall risk.
It uses a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16.
The total score (Fall Risk) ranges from 0 to 28, with higher scores indicating better balance and gait performance (19 or below=High risk of falls; 20-23=Moderate risk of falls; 24-28=Low risk of falls).
|
T1: up to 2 weeks
|
|
Motor Coordination
Time Frame: T2: up to 3 weeks
|
Performance Oriented Mobility Assesment (Tinetti Balance Scale) is an administered 16-item task-oriented test that measures gait and balance abilities, primarily to assess fall risk.
It uses a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16.
The total score (Fall Risk) ranges from 0 to 28, with higher scores indicating better balance and gait performance (19 or below=High risk of falls; 20-23=Moderate risk of falls; 24-28=Low risk of falls).
|
T2: up to 3 weeks
|
|
Motor Coordination
Time Frame: T3: up to 3 months
|
Performance Oriented Mobility Assesment (Tinetti Balance Scale) is an administered 16-item task-oriented test that measures gait and balance abilities, primarily to assess fall risk.
It uses a 3-point ordinal scale of 0, 1 and 2. Gait is scored over 12 and balance is scored over 16.
The total score (Fall Risk) ranges from 0 to 28, with higher scores indicating better balance and gait performance (19 or below=High risk of falls; 20-23=Moderate risk of falls; 24-28=Low risk of falls).
|
T3: up to 3 months
|
|
Balance
Time Frame: T0: Baseline
|
Berg Balance Scale is a 14-item objective measure that assesses static balance and fall risk, item-level scores range from 0-4, determined by ability to perform the assessed activity.
The total score ranges from 0 to 56, with higher scores indicating better balance.
A score of less than 45 suggests an increased risk of falling.
|
T0: Baseline
|
|
Balance
Time Frame: T1: up to 2 weeks
|
Berg Balance Scale is a 14-item objective measure that assesses static balance and fall risk, item-level scores range from 0-4, determined by ability to perform the assessed activity.
The total score ranges from 0 to 56, with higher scores indicating better balance.
A score of less than 45 suggests an increased risk of falling.
|
T1: up to 2 weeks
|
|
Balance
Time Frame: T2: up to 3 weeks
|
Berg Balance Scale is a 14-item objective measure that assesses static balance and fall risk, item-level scores range from 0-4, determined by ability to perform the assessed activity.
The total score ranges from 0 to 56, with higher scores indicating better balance.
A score of less than 45 suggests an increased risk of falling.
|
T2: up to 3 weeks
|
|
Balance
Time Frame: T3: up to 3 months
|
Berg Balance Scale is a 14-item objective measure that assesses static balance and fall risk, item-level scores range from 0-4, determined by ability to perform the assessed activity.
The total score ranges from 0 to 56, with higher scores indicating better balance.
A score of less than 45 suggests an increased risk of falling.
|
T3: up to 3 months
|
|
Kinesiophobia
Time Frame: T0: Baseline
|
The Tampa Scale for Kinesiophobia (TSK) is a validated self-report questionnaire designed to assess the fear of movement or (re)injury in individuals experiencing pain or musculoskeletal disorders. The TSK consists of 13 items (Italian validated version), each rated on a 4-point Likert scale, ranging from 1 ("Strongly Disagree") to 4 ("Strongly Agree"). The scores are summed to yield a total score ranging from 13 to 52, with higher scores indicating greater levels of kinesiophobia. The TSK includes two subscales: 1.Activity Avoidance, with a score ranging from 6 to 24; 2.Harm Beliefs, with a score ranging from 7 to 28. Higher scores on both the Activity Avoidance and Harm Beliefs subscales indicate greater levels of kinesiophobia, reflecting increased fear of movement due to injury concerns (Activity Avoidance subscale) or harmful beliefs about physical activity (Harm Beliefs subscale). |
T0: Baseline
|
|
Kinesiophobia
Time Frame: T2: up to 3 weeks
|
The Tampa Scale for Kinesiophobia (TSK) is a validated self-report questionnaire designed to assess the fear of movement or (re)injury in individuals experiencing pain or musculoskeletal disorders. The TSK consists of 13 items (Italian validated version), each rated on a 4-point Likert scale, ranging from 1 ("Strongly Disagree") to 4 ("Strongly Agree"). The scores are summed to yield a total score ranging from 13 to 52, with higher scores indicating greater levels of kinesiophobia. The TSK includes two subscales: 1.Activity Avoidance, with a score ranging from 6 to 24; 2.Harm Beliefs, with a score ranging from 7 to 28. Higher scores on both the Activity Avoidance and Harm Beliefs subscales indicate greater levels of kinesiophobia, reflecting increased fear of movement due to injury concerns (Activity Avoidance subscale) or harmful beliefs about physical activity (Harm Beliefs subscale). |
T2: up to 3 weeks
|
|
Kinesiophobia
Time Frame: T3: up to 3 months
|
The Tampa Scale for Kinesiophobia (TSK) is a validated self-report questionnaire designed to assess the fear of movement or (re)injury in individuals experiencing pain or musculoskeletal disorders. The TSK consists of 13 items (Italian validated version), each rated on a 4-point Likert scale, ranging from 1 ("Strongly Disagree") to 4 ("Strongly Agree"). The scores are summed to yield a total score ranging from 13 to 52, with higher scores indicating greater levels of kinesiophobia. The TSK includes two subscales: 1.Activity Avoidance, with a score ranging from 6 to 24; 2.Harm Beliefs, with a score ranging from 7 to 28. Higher scores on both the Activity Avoidance and Harm Beliefs subscales indicate greater levels of kinesiophobia, reflecting increased fear of movement due to injury concerns (Activity Avoidance subscale) or harmful beliefs about physical activity (Harm Beliefs subscale). |
T3: up to 3 months
|
|
Well-being and Mental Health
Time Frame: T0: Baseline
|
Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) is a self-report questionnaire designed to assess psychological distress and monitor treatment response. It consists of 34 items evaluating emotional state and perceived well-being over the past week, rated on a 5-point Likert scale from 0 ("Not at all") to 4 ("Most or all of the time"). The total score is calculated as the mean of all item scores and can be reported in two ways: 1.Raw score: The mean of all item scores (range: 0-4). 2.Standardized score: Obtained by multiplying the raw score by 10, yielding a scale from 0 to 40. The data presented in the results refer to the raw score. Score Interpretation: 0.00-0.99: No clinical distress or minimal risk. 1.00-1.99: Mild distress, potentially significant. 2.00-2.99: Moderate distress, generally indicative of the need for intervention. 3.00-4.00: Severe distress, highly indicative of the need for immediate clinical intervention. |
T0: Baseline
|
|
Well-being and Mental Health
Time Frame: T2: up to 3 weeks
|
Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) is a self-report questionnaire designed to assess psychological distress and monitor treatment response. It consists of 34 items evaluating emotional state and perceived well-being over the past week, rated on a 5-point Likert scale from 0 ("Not at all") to 4 ("Most or all of the time"). The total score is calculated as the mean of all item scores and can be reported in two ways: 1.Raw score: The mean of all item scores (range: 0-4). 2.Standardized score: Obtained by multiplying the raw score by 10, yielding a scale from 0 to 40. The data presented in the results refer to the raw score. Score Interpretation: 0.00-0.99: No clinical distress or minimal risk. 1.00-1.99: Mild distress, potentially significant. 2.00-2.99: Moderate distress, generally indicative of the need for intervention. 3.00-4.00: Severe distress, highly indicative of the need for immediate clinical intervention. |
T2: up to 3 weeks
|
|
Well-being and Mental Health
Time Frame: T3: up to 3 months
|
Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) is a self-report questionnaire designed to assess psychological distress and monitor treatment response. It consists of 34 items evaluating emotional state and perceived well-being over the past week, rated on a 5-point Likert scale from 0 ("Not at all") to 4 ("Most or all of the time"). The total score is calculated as the mean of all item scores and can be reported in two ways: 1.Raw score: The mean of all item scores (range: 0-4). 2.Standardized score: Obtained by multiplying the raw score by 10, yielding a scale from 0 to 40. The data presented in the results refer to the raw score. Score Interpretation: 0.00-0.99: No clinical distress or minimal risk. 1.00-1.99: Mild distress, potentially significant. 2.00-2.99: Moderate distress, generally indicative of the need for intervention. 3.00-4.00: Severe distress, highly indicative of the need for immediate clinical intervention. |
T3: up to 3 months
|
|
Physical Functioning and Psychological Well-being
Time Frame: T0: Baseline
|
Pediatric Outcomes Data Collection (PODCI) evaluates functional health status through an 83-item questionnaire, and uses domain-specific scales.
Each scale generates a score ranging from 0 to 100, with higher scores indicating better functioning or less impairment.
|
T0: Baseline
|
|
Physical Functioning and Psychological Well-being
Time Frame: T1: up to 2 weeks
|
Pediatric Outcomes Data Collection (PODCI) evaluates functional health status through an 83-item questionnaire, and uses domain-specific scales.
Each scale generates a score ranging from 0 to 100, with higher scores indicating better functioning or less impairment.
|
T1: up to 2 weeks
|
|
Physical Functioning and Psychological Well-being
Time Frame: T2: up to 3 weeks
|
Pediatric Outcomes Data Collection (PODCI) evaluates functional health status through an 83-item questionnaire, and uses domain-specific scales.
Each scale generates a score ranging from 0 to 100, with higher scores indicating better functioning or less impairment.
|
T2: up to 3 weeks
|
|
Physical Functioning and Psychological Well-being
Time Frame: T3: up to 3 months
|
Pediatric Outcomes Data Collection (PODCI) evaluates functional health status through an 83-item questionnaire, and uses domain-specific scales.
Each scale generates a score ranging from 0 to 100, with higher scores indicating better functioning or less impairment.
|
T3: up to 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Information on the Functioning and Disability of an Individual
Time Frame: T0
|
Functional Independence Measure (FIM) is a validated clinician-administered tool designed to assess functional independence in individuals with neurological or musculoskeletal conditions.
It evaluates the level of assistance required for daily activities across six domains: self-care, sphincter control, mobility, locomotion, communication, and social cognition.
The FIM consists of 18 items, each rated on a 7-point ordinal scale (1 = total assistance, 7 = complete independence), with total scores ranging from 18 to 126.
Higher scores indicate greater functional independence.
|
T0
|
|
Information on the Functioning and Disability of an Individual
Time Frame: T3
|
Functional Independence Measure (FIM) is a validated clinician-administered tool designed to assess functional independence in individuals with neurological or musculoskeletal conditions.
It evaluates the level of assistance required for daily activities across six domains: self-care, sphincter control, mobility, locomotion, communication, and social cognition.
The FIM consists of 18 items, each rated on a 7-point ordinal scale (1 = total assistance, 7 = complete independence), with total scores ranging from 18 to 126.
Higher scores indicate greater functional independence.
|
T3
|
|
Kinesiophobia
Time Frame: T1
|
The Tampa Scale for Kinesiophobia (TSK) is a validated self-report questionnaire designed to assess the fear of movement or (re)injury in individuals experiencing pain or musculoskeletal disorders. The TSK consists of 13 items (Italian validated version), each rated on a 4-point Likert scale, ranging from 1 ("Strongly Disagree") to 4 ("Strongly Agree"). The scores are summed to yield a total score ranging from 13 to 52, with higher scores indicating greater levels of kinesiophobia. The TSK includes two subscales: 1.Activity Avoidance, with a score ranging from 6 to 24; 2.Harm Beliefs, with a score ranging from 7 to 28. Higher scores on both the Activity Avoidance and Harm Beliefs subscales indicate greater levels of kinesiophobia, reflecting increased fear of movement due to injury concerns (Activity Avoidance subscale) or harmful beliefs about physical activity (Harm Beliefs subscale). |
T1
|
|
Well-being and Mental Health
Time Frame: T1
|
Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM) is a self-report measure of psychological distress designed to be administered during a course of treatment to determine treatment response. It compries 34 questions about how the participants have been feeling over the last week, using a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Most or all of the time"). The total score is calculated as the mean of all item scores (ranging from 0 to 4) and can be reported either as a raw score or standardized (e.g., multiplying the mean by 10 to obtain a score on a 0-40 scale). Score Interpretation: 0-0.99: No clinical distress or minimal risk. 1.00-1.99: Mild distress, potentially significant. 2.00-2.99: Moderate distress, generally indicative of a need for intervention. 3.00-4.00: Severe distress, highly indicative of immediate clinical intervention. |
T1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Luca Sangiorgi, MD, PhD, IRCCS Istituto Ortopedico Rizzoli
Publications and helpful links
General Publications
- Cornaglia Ferraris P. [Adventure therapy: principles, practice, perspectives.]. Recenti Prog Med. 2018 Oct;109(10):487-493. doi: 10.1701/3010.30086. Italian.
- MacLachlan M. Sailing as an Intervention. In: MacLachlan M, editor. Maritime Psychology: Research in Organizational & Health Behavior at Sea. Cham: Springer International Publishing; 2017. https://doi.org/10.1007/978-3-319-45430-6_10
- Thompson T, Lamont-Robinson C, Williams V. At sea with disability! Transformative learning in medical undergraduates voyaging with disabled sailors. Med Educ. 2016 Aug;50(8):866-79. doi: 10.1111/medu.13087.
- Recio AC, Becker D, Morgan M, Saunders NR, Schramm LP, McDonald JW 3rd. Use of a virtual reality physical ride-on sailing simulator as a rehabilitation tool for recreational sports and community reintegration: a pilot study. Am J Phys Med Rehabil. 2013 Dec;92(12):1104-9. doi: 10.1097/PHM.0000000000000012.
- Tracey D, Gray T, Truong S, Ward K. Combining Acceptance and Commitment Therapy With Adventure Therapy to Promote Psychological Wellbeing for Children At-Risk. Front Psychol. 2018 Aug 27;9:1565. doi: 10.3389/fpsyg.2018.01565. eCollection 2018.
- Capurso, M.; Borsci, S. Effects of a Tall Ship Sail Training Experience on Adolescents' Self-Concept. International Journal of Educational Research 2013, 58, 15-24. https://doi.org/10.1016/j.ijer.2013.01.004.
- Gill E, Goldenberg M, Starnes H, Phelan S. Outdoor adventure therapy to increase physical activity in young adult cancer survivors. J Psychosoc Oncol. 2016 May-Jun;34(3):184-99. doi: 10.1080/07347332.2016.1157718. Epub 2016 Mar 3.
- Zebrack B, Kwak M, Sundstrom L. First Descents, an adventure program for young adults with cancer: who benefits? Support Care Cancer. 2017 Dec;25(12):3665-3673. doi: 10.1007/s00520-017-3792-7. Epub 2017 Jun 27.
- Aprile I, Iacovelli C, Iuvone L, Imbimbo I, Cruciani A, Pecchioli C, Manozzi FM, Padua L. Use of a Virtual-Technological Sailing Program to Prepare Children With Disabilities for a Real Sailing Course: Effects on Balance and Quality of Life. J Child Neurol. 2016 Jul;31(8):1074-80. doi: 10.1177/0883073816638756. Epub 2016 Mar 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Diseases
- Musculoskeletal Diseases
- Neoplasms
- Genetic Diseases, Inborn
- Connective Tissue Diseases
- Neoplasms by Histologic Type
- Neoplastic Syndromes, Hereditary
- Neoplasms, Connective and Soft Tissue
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Osteochondrodysplasias
- Bone Diseases, Developmental
- Collagen Diseases
- Hyperostosis
- Osteogenesis Imperfecta
- Osteochondroma
- Exostoses, Multiple Hereditary
- Osteochondromatosis
- Enchondromatosis
- Exostoses
Other Study ID Numbers
- 115/2024/Sper/IOR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteogenesis Imperfecta
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Angitia Biopharmaceuticals Guangzhou LimitedNot yet recruitingA Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR) (EIR)Osteogenesis Imperfecta (OI)China
-
Istituto Ortopedico RizzoliRecruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta (OI)Italy
-
Novartis PharmaceuticalsCompletedOsteogenesis ImperfectaUnited States
-
Shriners Hospitals for ChildrenNovartisCompleted
-
University Hospital, GhentUniversity Ghent; Brittle Bone Society; Osteogenesis Imperfecta FederationRecruiting
-
AmgenTerminatedOsteogenesis Imperfecta (OI)Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
-
Angitia Incorporated LimitedRecruitingOsteogenesis Imperfecta (OI)United States, France, Netherlands, Australia, Denmark, United Kingdom, Canada, Argentina
Clinical Trials on 5-day sailing activity
-
Istituto Ortopedico RizzoliCompleted
-
VA Salt Lake City Health Care SystemWithdrawnSubstance Use Disorders | Psychiatric DisorderUnited States
-
Hillerod Hospital, DenmarkUnknownPhysical Activity | Acute Ischemic Stroke | AccelerometerDenmark
-
Boehringer IngelheimCompleted
-
Boston University Charles River CampusNot yet recruitingAging | Memory | Noninvasive Brain Stimulation
-
St. Antonius Hospital GronauCompleted
-
Biolux Research Holdings, Inc.Unknown
-
Beth Israel Deaconess Medical CenterBoston IVFCompletedInfertilityUnited States
-
IgenomixUnknown
-
Massachusetts General HospitalReeboks BOKSCompletedPhysical Activity | Overweight and Obesity | Fitness | AffectUnited States